26.51
+0.49(+1.88%)
Currency In USD
| Previous Close | 26.02 |
| Open | 26.04 |
| Day High | 26.63 |
| Day Low | 26.01 |
| 52-Week High | 27.64 |
| 52-Week Low | 18.17 |
| Volume | 424,527 |
| Average Volume | 719,741 |
| Market Cap | 1.21B |
| PE | 56.4 |
| EPS | 0.47 |
| Moving Average 50 Days | 23.63 |
| Moving Average 200 Days | 24.44 |
| Change | 0.49 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $344.42 as of December 27, 2025 at a share price of $26.51. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $454.09 as of December 27, 2025 at a share price of $26.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
GlobeNewswire Inc.
Dec 02, 2025 1:00 PM GMT
-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported -- BRISBA
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical
GlobeNewswire Inc.
Nov 26, 2025 9:01 PM GMT
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to t